SOUTH PLAINFIELD, N.J., July 28 /PRNewswire/ -- PTC Therapeutics, Inc.
(PTC) today announced that the company was awarded the Art of Industry
Partnership Award by the Genetic Alliance. Genetic Alliance presents the
Art of Listening, Art of Advocacy, and Art of Industry Partnership Awards
annually.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )
"The Art of Industry Partnership Award honors a for-profit company that
models the benefits of creative partnerships between consumer advocates and
industry in advancing understanding and treatment of genetic conditions,"
stated Sharon Terry, chief executive of the Genetic Alliance. "PTC
Therapeutics has proven itself a leader in establishing productive,
effective partnerships between government, advocacy organizations and
physicians to advance drug development in areas of high unmet medical need;
areas where few other pharmaceutical companies have been willing to focus.
We are proud to acknowledge their leadership with this award."
PTC has established relationships and partnerships with several
advocacy groups, including the Muscular Dystrophy Association, the Parent
Project Muscular Dystrophy, the Cystic Fibrosis Foundation, the Spinal
Muscular Atrophy Foundation, and Fight SMA. Collectively these groups have
provided significant funding to support research in multiple genetic
disorders. Importantly, the advocacy community has also been essential in
helping establishing clinical endpoints and facilitating better
understanding the challenges and needs of those affected by genetic
disorders. The result of this support is that PTC now has established one
of the broadest genetic disorders pipelines in the industry with over
eleven programs addressing Duchenne muscular dystrophy, cystic fibrosis,
and spinal muscular atrophy.
"We are honored to receive this award from the Genetic Alliance. Our
relationships with the advocacy community have been essential in our quest
to develop innovative therapeutics in genetic disorders," stated Stuart W.
Peltz, Ph.D., president and chief executive officer of PTC Therapeutics.
"We look forward to continuing these valuable and productive collaborations
with advocacy groups as well as the broader patient community."
About Genetic Alliance
Genetic Alliance transforms health through genetics, using an
environment of openness centered on the health of individuals, families,
and communities. Genetic Alliance brings together diverse stakeholders that
create novel partnerships in advocacy; integrates individual, family, and
community perspectives to improve health systems; and revolutionizes access
to information to enable translation of research into services and
individualized decision making.
About PTC Therapeutics Inc.
PTC is a biopharmaceutical company focused on the discovery,
development and commercialization of orally administered, proprietary,
small-molecule drugs that target post-transcriptional control processes.
Post-transcriptional control processes regulate the rate and timing of
protein production and are of central importance to proper cellular
function. PTC's internally-discovered pipeline addresses multiple
therapeutic areas, including genetic disorders, oncology and infectious
diseases. In addition, PTC has developed proprietary technologies and
extensive knowledge of post-transcriptional control processes that it
applies in its drug discovery and development activities, including the
Gene Expression Modulation by Small-molecules (GEMS) technology platform,
which has been the basis for collaborations with leading pharmaceutical and
biotechnology companies such as Genzyme, Pfizer, Celgene, CV Therapeutics
and Schering-Plough. For more information, visit PTC's website,
http://www.ptcbio.com.
SOURCE PTC Therapeutics, Inc.
 back to top
Related links:
http://www.ptcbio.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Investors and Media, Jane Baj, PTC
Therapeutics, Inc., +1-908-912-9167, jbaj@ptcbio.com; Sheryl
Seapy, Pure Communications, +1-949-608-0841,
sheryl@purecommunicationsinc.com, for PTC
|
